Mutant MT-SP1 proteases with altered substrate specificity or activity
US9359598B2 · kind B2 · utility
5Cited by
46References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 20, 2013 |
| Grant date | Jun 7, 2016 |
| Priority date | — |
| Expiry date | Sep 29, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N9/6424
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
MT-SP1 mutein proteases with altered specificity for the target molecules they cleave can be used to treat human diseases, such as cancer. Cleaving VEGF or VEGFR at certain substrate sequences with wild-type and mutein MT-SP1 proteases can be used to treat pathologies associated with angiogenesis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.